Ligand Pharmaceuticals (Ligand Pharmaceuticals) Total Inventories

: $24.0 Mil (As of Dec. 2023)

View and export this data going back to 1995. Start your Free Trial

Ligand Pharmaceuticals's total inventories for the quarter that ended in Dec. 2023 was $24.0 Mil. Ligand Pharmaceuticals's average total inventories from the quarter that ended in Sep. 2023 to the quarter that ended in Dec. 2023 was $24.7 Mil.

In Ben Graham's calculation of Net-Net Working Capital, inventory is only considered worth half of its book value. Ligand Pharmaceuticals's Net-Net Working Capital per share for the quarter that ended in Dec. 2023 was $6.87.

Days Inventory indicates the number of days of goods in sales that a company has in the inventory. Ligand Pharmaceuticals's Days Inventory for the three months ended in Dec. 2023 was 1,372.39.

Inventory Turnover measures how fast the company turns over its inventory within a year. Ligand Pharmaceuticals's Inventory Turnover for the quarter that ended in Dec. 2023 was 0.07.

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue. Ligand Pharmaceuticals's Inventory-to-Revenue for the quarter that ended in Dec. 2023 was 0.88.

Ligand Pharmaceuticals Total Inventories Historical Data

The historical data trend for Ligand Pharmaceuticals's Total Inventories can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ligand Pharmaceuticals Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Inventories

Get a 7-Day Free Trial

7.30

26.49

27.33

13.29

23.97

Ligand Pharmaceuticals Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Total Inventories	Get a 7-Day Free Trial															13.29	14.01	26.91	25.39	23.97

Ligand Pharmaceuticals Total Inventories Calculation

Total Inventories includes the raw materials, work-in-process goods and completely finished goods of a company. It is a portion of a company's current assets.

Ligand Pharmaceuticals (NAS:LGND) Total Inventories Explanation

Inventory control is an important part of business operation. If a company does not have enough inventory, it may not be able to meet customers' required delivery time. If it has too much inventory, the cost of holding the inventory can be high.

1. In Ben Graham's calculation of Net-Net Working Capital (NNWC), inventory is only considered worth half of its book value.

Ligand Pharmaceuticals's Net-Net Working Capital Per Share for the quarter that ended in Dec. 2023 is

	Net-Net Working Capital Per Share (Q: Dec. 2023 )
=	(Cash And Cash Equivalents	+	0.75 * Accounts Receivable	+	0.5 * Total Inventories	-	Total Liabilities
-	Preferred Stock	-	Minority Interest)	/	Shares Outstanding (EOP)
=	(170.309	+	0.75 * 32.917	+	0.5 * 23.969	-	86.303
-	0	-	0)	/	17.556
=	6.87

2. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Ligand Pharmaceuticals's Days Inventory for the three months ended in Dec. 2023 is calculated as:

Days Inventory	=	Average Total Inventories (Q: Dec. 2023 )	/	Cost of Goods Sold (Q: Dec. 2023 )	*	Days in Period
	=	24.6805	/	1.641	*	365 / 4
	=	1,372.39

3. Inventory Turnover measures how fast the company turns over its inventory within a year.

Ligand Pharmaceuticals's Inventory Turnover for the quarter that ended in Dec. 2023 is calculated as

Inventory Turnover	=	Cost of Goods Sold (Q: Dec. 2023 )	/	Average Total Inventories (Q: Dec. 2023 )
	=	1.641	/	24.6805
	=	0.07

4. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

Ligand Pharmaceuticals's Inventory to Revenue for the quarter that ended in Dec. 2023 is calculated as

Inventory-to-Revenue	=	Average Total Inventories (Q: Dec. 2023 )	/	Revenue (Q: Dec. 2023 )
	=	24.6805	/	28.101
	=	0.88

Be Aware

Manufacturers with durable competitive advantages have the advantage that the products they sell do not change, and therefore will never become obsolete. Buffett likes this advantage.

When identifying manufacturers with durable competitive advantage, look for inventory and net earnings that rise correspondingly. This indicates that the company is finding profitable ways to increase sales which called for an increase in inventory.

Manufacturers with inventories that spike up and down are indicative of competitive industries subject to boom and bust.

Ligand Pharmaceuticals Total Inventories Related Terms

Thank you for viewing the detailed overview of Ligand Pharmaceuticals's Total Inventories provided by GuruFocus.com. Please click on the following links to see related term pages.

Ligand Pharmaceuticals (Ligand Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ligand Pharmaceuticals Inc (NAS:LGND) » Definitions » Total Inventories

Comparable Companies

Traded in Other Exchanges

LGDN:Germany

Address

3911 Sorrento Valley Boulevard, Suite 110, San Diego, CA, USA, 92121

Website

https://www.ligand.com

Ligand Pharmaceuticals Inc is a biopharmaceutical company focused on developing and acquiring technologies that aid in creating medicine. The company has partnerships and license agreements with various pharmaceutical and biotechnology companies. Ligand's business model is based on drug discovery, early-stage drug development, product reformulation, and partnerships. The company's revenue consists of three primary elements: royalties from commercialized products, license and milestone payments, and sale of its trademarked Captisol material.

Executives

Martine Zimmermann	director	C/O LIGAND PHARMACEUTICALS INCORPORATED, 3911 SORRENTO VALLEY BOULEVARD SUITE 110, SAN DIEGO CA 92121
Todd C Davis	director	11119 NORTH TORREY PINES ROAD, SUITE 200, LA JOLLA CA 92037
Andrew Reardon	officer: CHIEF LEGAL OFFICER &	C/O LIGAND PHARMACEUTICALS INCORPORATED, 3911 SORRENTO VALLEY BLVD, SUITE 110, SAN DIEGO CA 92121
Octavio Espinoza	officer: Chief Financial Officer	C/O LIGAND PHARMACEUTICALS INC, 3911 SORRENTO VALLEY BOULEVARD, STE 110, SAN DIEGO CA 92121
John W Kozarich	director	10275 SCIENCE CENTER DR, SAN DIEGO CA 92121
Stephen L Sabba	director	DORSET MANAGEMENT CORP, 485 UNDERHILL BLVD SUITE 205, SYOSSET NY 11791
John L Higgins	officer: CEO & President	11119 NORTH TORREY PINES ROAD, SUITE 200, LA JOLLA CA 92037
Jason Haas	director	C/O SYROS PHARMACEUTICALS, INC., 35 CAMBRIDGEPARK DRIVE, CAMBRIDGE MA 02140
Matthew W Foehr	officer: EVP and COO	11119 NORTH TORREY PINES RD #200, LA JOLLA CA 92037
John L Lamattina	director	81 WYMAN ST, POST OFFICE BOX 9046, WALTHAM MA 02454
Jennifer R. Cochran	director	C/O LIGAND PHARMACEUTICALS INC, 3911 SORRENTO VALLEY BOULEVARD, STE 100, SAN DIEGO CA 92121
Charles S Berkman	officer: Asso. Gen. Counsel, Secretary	11085 NORTH TORREY PINES ROAD, SUITE 300, LA JOLLA CA 92037
Sunil Patel	director	11085 NORTH TORREY PINES RD., SUITE 300, LA JOLLA CA 92037
Goldman Sachs Group Inc	10 percent owner	200 WEST STREET, NEW YORK NY 10282
Goldman Sachs & Co. Llc	10 percent owner	200 WEST STREET, NEW YORK NY 10282